Participated · Series B · Oct 2025

Founded in 2019, PineTree Therapeutics is building AbReptor™, a proprietary platform that creates modular bispecific and multispecific degraders capable of eliminating membrane-bound and extracellular proteins that drive tumor growth and therapeutic resistance. The technology has shown strong preclinical efficacy and safety against receptor tyrosine kinases, including those refractory to existing TKIs and immune checkpoint inhibitors. Beyond oncology, the company believes its degraders may provide new approaches for inflammatory and immunology indications. PineTree is also exploring a novel class of degrading antibody–drug conjugates and trispecific degraders to enhance durability and tolerability. In July 2024 it inked an AstraZeneca collaboration that carries more than $500 million in potential milestones and royalties around its preclinical EGFR degrader. Proceeds from its recent Series B financing will fund IND-enabling work, first-in-human studies, and expansion of its degrader portfolio, while supporting additional strategic collaborations. The company remains pre-revenue and has not yet entered clinical trials, putting near-term emphasis on advancing lead candidates into Phase I.

Participated · Series A · Mar 2021

Master Meditech Inc. announced a KRW 8 billion Series A funding round closed on March 29, 2021. The articles report participation from a mix of corporate and investment firms. Named participants include Samho Green Investment, Paratus Investment (and a Paratus‑managed fund, CP Partners LLC), Spring Camp, Huons Co., Pharmbio Co., INNOCENCE Co.Ltd, King Mind Partners, and Foresite‑Cape Bio New Technology Investment Association. The coverage does not disclose valuation, use of proceeds, revenue, or user metrics. No founding year or company location is provided in the articles.

Participated · Equity · Dec 2018

Medi Futures commercializes products built on an ultrasonic platform, including ultrasonic endoscopic disk surgical instruments and enzyme-free ultrasound stem cell separators. The company has recently developed and exported medical sutures with high-precision anchoring points (barbed sutures). It operates from Seoul, South Korea, and is a member of the K-ICT Born2Global Centre. Medi Futures also participated in a training program at Medtronic’s Asia‑Pacific Headquarters. The company raised US$5M in funding through common stocks to support its operations and regulatory progress. The investment is expected to accelerate efforts to obtain FDA and CFDA approvals.

Participated · Series A · Jan 2018

Insignary offers a SaaS and server-based security tool, Insignary Clarity™, that enables proactive scanning of software binaries for known security vulnerabilities and potential license compliance issues. Clarity uses a fingerprint-based technology that operates at the binary level without requiring source code or reverse engineering. The company also publishes TruthIsIntheBinary.com and provides cloud-based binary-scanning solutions. BearingPoint made a strategic investment to support Insignary’s growth and go-to-market activities. The funding is intended to help Insignary meet growing demand in the EU, the US and Asia. Insignary is venture-backed and was founded in 2016. Insignary offers Insignary Clarity™, a SaaS and server-based security tool that proactively scans software binaries for known security vulnerabilities and potential license compliance issues. The company’s fingerprint-based technology operates at the binary level without requiring source code or reverse engineering. Its solution is used by software developers, value-added resellers, systems integrators and security managed service providers to oversee deployments and take preventive action before delivery. Led by CEO Tae-Jin (TJ) Kang, Insignary intends to use new capital to scale to meet demand across the E.U., U.S. and Asia for businesses, MSPs, resellers and auditors. Financially, the company secured a $2M Series A and has raised $4M in total venture funding to date. The business is headquartered in Sunnyvale, California.